Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Shire to Acquire Fibrotech for $75M Plus Milestones

Published: Friday, May 02, 2014
Last Updated: Friday, May 02, 2014
Bookmark and Share
Shire has agreed to purchase Fibrotech for an upfront payment of $75M and certain contingent payments based on the achievement of development and regulatory milestones.

Shire will undertake the further development of Fibrotech’s lead product FT011, which has completed a Phase 1A study in healthy volunteers and is currently in a Phase 1B study in patients with diabetic nephropathy. Subject to successful completion of this trial, the first Phase 2 study is expected to be initiated to enroll Focal Segmental Glomerulosclerosis (FSGS) patients next year. FSGS is a rare disease that affects the kidney’s filtering system causing serious fibrosis (scarring). The majority (85%) of cases are idiopathic and most of the patients progress to End Stage Renal Disease. In addition to the lead compound FT011, Shire acquires Fibrotech’s library of novel molecules including another molecule, FT061, in pre-clinical development that has a similar mode of action to FT011. It is an oral small molecule with the potential to address both the inflammatory and pro-fibrotic components of fibrosis.

The closing of the acquisition is subject to customary conditions, including approval of Australia's Foreign Investment Review Board.

Phil Vickers, Shire Head of Research & Development, commented:

“The acquisition of Fibrotech is a strategic step in expanding Shire’s pipeline with a novel, clinical stage anti-fibrotic agent that strengthens our growing and innovative portfolio targeting renal and fibrotic diseases. There have been significant advances in the scientific understanding of fibrosis and the use of biomarkers to support clinical development – which makes now a good time to invest in these promising assets targeting a novel mechanism of action.”

Dr Chris Nave, a founding partner of Brandon Capital Partners and Principal Executive of the Medical Research Commercialisation Fund, added:

“Fibrotech was the MRCF’s very first investment, so this deal represents a significant validation of our approach to commercialise the very best discoveries from Australia’s leading medical research institutes. To get such an impressive return on our investment speaks to the quality of the science at the University of Melbourne, St Vincent's Institute of Medical Research and Bio21 Institute.”

Dr Peter Devine, CEO of Uniseed added:

“This deal is an endorsement of the Uniseed concept: to facilitate commericalisation of university intellectual property. Having supported Fibrotech since its inception, Uniseed is proud to be associated with such a significant partnership.”

Prof. Darren Kelly, CEO of Fibrotech concluded:

“The team at Fibrotech are very excited about this acquisition as Shire are strategically aligned with our commitment to renal and fibrotic conditions, including rare diseases – areas of high unmet medical need.  This acquisition will have significant benefit to the Australian biotechnology sector and highlights the importance of commercialisation and collaboration between academia and industry.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Shire to Attain Enhanced CINRYZE® Manufacturing Flexibility and Capacity
The company enters into new agreement with Sanquin.
Thursday, August 27, 2015
Shire Acquires Foresight Biotherapeutics
With the acquisition, Shire acquires the global rights to FST-100 a therapy in late-stage development for the treatment of infectious conjunctivitis, an ocular surface condition commonly referred to as pink eye.
Tuesday, August 04, 2015
Shire to Relocate Over 500 Jobs to Massachusetts
Establishes Lexington, Mass., as Company’s U.S. operational headquarters.
Friday, November 21, 2014
Shire Acquires Lumena Pharmaceuticals
Lumena's late stage rare disease pipeline assets are seen as a perfect combination for Shire’s Gastrointestinal (GI) presence.
Tuesday, May 13, 2014
Shire Announces European Approval of Manufacturing Facility for VPRIV®
EMA approval adds significant capacity for the manufacture of Shire’s enzyme replacement therapies.
Thursday, February 23, 2012
Scientific News
Genetic Defences of Bacteria Don’t Aid Antibiotic Resistance
Genetic responses to the stresses caused by antibiotics don’t help bacteria to evolve a resistance to the medications, according to a new study by Oxford University researchers.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
Horse Illness Shares Signs of Human Disease
Horses with a rare nerve condition have similar signs of disease as people with conditions such as Alzheimer’s, a study has found.
How a Molecular Motor Untangles Protein
Diseases such as Alzheimer’s, Parkinson’s and prion diseases, all involve “tangled” proteins.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos